GFN•TV will bring the conference's platform for rational and inclusive debate on the future role of safer nicotine products and tobacco harm reduction to an audience all year round. GFN•TV will also be broadcasting live from Warsaw in June. Tune in to hear world-leading experts, tobacco harm reduction advocates and nicotine consumers discuss the latest scientific, regulatory and policy developments. From our unique annual event, to year-round reporting of the issues that matter in tobacco harm reduction, GFN has got it covered.
DOOMED TO FAIL | Colin Mendelsohn explains Australia's new vape regulations
New legislation in Australia means that vapes can only be bought in pharmacies, with e-liquid only available in three flavours. What are the likely consequences of this, in a country where the black market for vaping products is already booming?
Science is an enabler at Japan Tobacco International, driving innovation in risk-reduced tobacco products and reinforcing its position when responding to critics. 'Each scientific study is a piece of the puzzle,' says Ian Jones, V.P. of the Scientific Product Assessment Center at JTI.
Featuring: IAN JONES V.P., Scientific Product Assessment Center Japan Tobacco International
📅 10 Sep 2024
A South African Perspective on Tobacco Harm Reduction | GFN Voices 2024 #5
In today's GFN Voices episode, Kurt Yeo explore the crucial relationship between economics, health, and tobacco harm reduction. With a focus on South Africa, we delve into the burden tobacco places on public health, the economic challenges it creates, and how harm reduction strategies could be the key to a healthier future.
📅 6 Sep 2024
What's the Truth about Nicotine? | GFN Voices 2024 #4
In this insightful discussion, Liza Katsiashvili, Andrzej Fal and Ethan Nadelmann tackle the growing misconceptions surrounding vaping and tobacco harm reduction. Learn how misinformation, fueled by media and powerful institutions like the WHO, is shaping public opinion and preventing effective harm reduction strategies.
📅 3 Sep 2024
From Oversight to Action: Addressing Smoking Rates in Vulnerable Populations | #GFN24
English subtitles are available through the YouTube 'CC' button!
It is widely recognized that smoking rates among key and vulnerable populations surpass those of other groups. However, across much of the globe, support services often overlook this issue. Consequently, many will face mortality not due to their substance use or mental health conditions, but rather as a result of smoking-related diseases. This session aims to discuss the reasons for this oversight, with a particular emphasis on Eastern Europe and Central Asia, and to generate ideas for effective interventions to address this critical issue.
📅 30 Aug 2024
GFN.TV Interviews | Are Anti-THR Campaigners Guilty of Taking Lives?
Spreading misinformation about nicotine vaping to vulnerable populations leads to dire consequences, warns Kiran Sidhu, a leading THR writer-journalist for Filter.
Harnessing the power of physicians, consumer advocates and regulators to promote THR | #GFN24
In this insightful panel discussion, experts explore the complex relationship between healthcare professionals and users within the context of harm reduction. The panel delves into the challenges of communicating harm reduction strategies to society and policymakers, while addressing the needs and perspectives of both doctors and users.
What are the key insights from Global Forum on Nicotine? | GFN Voices 2024 #3
In this video, we dive into the highlights and key takeaways from a recent global advocacy conference. Hear from Michael Landl as he shares his favorite sessions, including an inspiring talk by Ethan Nadelmann. Learn about the importance of community, shared experiences, and effective strategies across different countries.
Featuring Michael Landl, Jarkyn Shadymanova and Pranay Ratna Sakya.
For Tobacco Harm Reduction (THR) to become widespread, affordable and appealing, reduced-risk alternatives to harmful tobacco products must be legally available and accessible. Achieving this requires sustained, substantial investment. The pace of harm reduction is closely tied to investment levels, influenced by potential risks and returns. Regulatory risk and uncertainty increase the returns required by investors, reducing available capital. Consequently:
- Reduced Investment in Product Development: Lower investment hinders the development of safer and more appealing products supported by scientific research. Without this, regulators are unlikely to consider them as effective harm-reduction solutions, and existing RRPs do not appeal to most smokers.
- Limited Accessibility in the Global South: Insufficient investment in cost reduction makes these products inaccessible to consumers in the Global South, home to 80% of harmful tobacco users.
- Hesitancy to Enter High-Risk Markets: Companies and investors are less likely to enter markets with high regulatory risk.
GFN 2024 Workshop - hosted by Pieter Vorster with panellists: Sud Patwardhan, Jonathan Fell and Marina Murphy
📅 16 Aug 2024
HEART PART | Imperial Brands Calls THR the ‘Right Thing to Do’
Supporting tobacco harm reduction is more than just pragmatic positioning to appease financial analysts and stakeholders. For Imperial Brands, one of the world’s major tobacco companies, THR represents a consumer-focused commitment to helping individuals switch to less harmful forms of tobacco. It's a strategy that balances both head and heart, reflecting a thoughtful approach to the future of safer nicotine products.
Featuring: Joe Thompson Group Science & Regulatory Affairs Director, Imperial Brands imperialbrandsplc.com
